JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target
JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.
A big investment bank started watching Nektar again and thinks its stock could be worth $65, but they're not saying it's a great buy or a bad pick—just middle of the road. When experts say 'neutral,' it means they see both good and not-so-good things, so watch how the company actually does to see if it moves in either direction.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.